Mounjaro is tirzepatide — a once-weekly injection from Eli Lilly, FDA-approved for type 2 diabetes. It's a dual GIP/GLP-1 receptor agonist, activating two gut-hormone pathways rather than one. The same molecule is sold as Zepbound for weight management and obstructive sleep apnea; Mounjaro is used off-label for weight loss. In trials, tirzepatide produced strong A1c and weight reductions and beat semaglutide in a head-to-head diabetes study (SURPASS-2).
Key takeaways
- Mounjaro is tirzepatide (Eli Lilly), a once-weekly injection for type 2 diabetes.
- It's a dual GIP/GLP-1 receptor agonist — two pathways, not one.
- Zepbound is the same molecule, approved for weight management and obstructive sleep apnea.
- In trials it delivered strong A1c and weight reductions and beat semaglutide in SURPASS-2.
- Dosing is stepped up gradually; it carries the class boxed thyroid warning.
What is Mounjaro?
Mounjaro is the brand name for tirzepatide, made by Eli Lilly. It's a once-weekly injection approved by the FDA to improve blood sugar in adults with type 2 diabetes, used alongside diet and exercise. What sets it apart from earlier drugs in the category is its mechanism: it's the first widely used dual GIP/GLP-1 receptor agonist.
| Fact | Detail |
|---|---|
| Maker | Eli Lilly |
| Drug class | Dual GIP/GLP-1 receptor agonist |
| Active ingredient | Tirzepatide |
| Approved use (Mounjaro) | Type 2 diabetes |
| Form & frequency | Once-weekly injection |
| Same molecule as | Zepbound (weight management, obstructive sleep apnea) |
How it works: two pathways, not one
Most GLP-1 drugs, like Ozempic, target a single receptor: GLP-1. Tirzepatide activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor — two different incretin hormones your gut releases in response to food. The idea is that engaging both pathways can produce larger effects on blood sugar and appetite than targeting GLP-1 alone. If you want the underlying biology, our primer on what GLP-1 is and how it works lays the groundwork; tirzepatide simply adds the second, GIP pathway on top.
Practically, that dual action is thought to be part of why tirzepatide has performed so strongly in trials for both glucose control and weight — the two effects covered in our broader guide to GLP-1s and weight loss.
What the trials showed
Tirzepatide was studied in the SURPASS program for diabetes and the SURMOUNT program for weight. Across these trials it produced strong reductions in A1c and body weight. The result that drew the most attention was SURPASS-2, a head-to-head diabetes trial in which tirzepatide outperformed semaglutide on blood-sugar and weight outcomes.
Two caveats are worth keeping in mind. First, trial averages describe groups, not individuals — your results depend on dose, adherence, diet and activity. Second, "beat semaglutide in one trial" is a meaningful finding but not the whole story; the drugs differ in approvals, dosing and tolerability too. For a direct comparison, see our post on Mounjaro vs. Ozempic.
Mounjaro vs. Zepbound: same drug, two names
This is the point that confuses people most. Mounjaro and Zepbound are the exact same molecule — tirzepatide — sold under two brand names for two different approved uses. Mounjaro carries the type 2 diabetes approval; Zepbound carries the approvals for chronic weight management and obstructive sleep apnea. When tirzepatide is prescribed specifically for weight, it's the Zepbound brand that holds that FDA indication — using Mounjaro for weight loss would be off-label.
Dosing and side effects
Like other drugs in the class, tirzepatide is started at a low dose and increased in steps to limit gastrointestinal side effects — the standard schedules are covered in our dosing guide. The most common side effects are digestive: nausea, diarrhea, and related symptoms, usually most noticeable after starting or increasing the dose; our side effects guide covers management and red flags.
Tirzepatide carries the same class boxed warning about thyroid C-cell tumors and is not for people with a personal or family history of medullary thyroid carcinoma or MEN2. As with every drug in this class, whether it's appropriate for you — and at what dose — is a decision for a clinician, not something to self-manage. We don't quote specific prices here; for how cost and coverage work, see our cost and insurance guide, and always confirm dosing against the current FDA label.
Frequently asked questions
What is Mounjaro?
Mounjaro is the brand name for tirzepatide, a once-weekly injectable medication from Eli Lilly that is FDA-approved to improve blood sugar in adults with type 2 diabetes. It is a dual GIP/GLP-1 receptor agonist, meaning it activates two gut-hormone pathways rather than the single GLP-1 pathway that older drugs in the class target.
Is Mounjaro the same as Zepbound?
They are the same active molecule — tirzepatide — sold under two brand names for different approved uses. Mounjaro is approved for type 2 diabetes, while Zepbound is approved for chronic weight management and obstructive sleep apnea. Same drug, different label and indication.
Is Mounjaro used for weight loss?
Mounjaro itself is approved for type 2 diabetes, and people taking it often lose weight as part of treatment. When tirzepatide is prescribed specifically for weight management, it is the Zepbound brand that carries that FDA approval. Using Mounjaro for weight loss would be an off-label use, and any such decision is one for a clinician.
How much weight can you lose on Mounjaro?
In clinical trials, tirzepatide produced strong reductions in both blood sugar (A1c) and body weight, and in a head-to-head diabetes study (SURPASS-2) it outperformed semaglutide. Individual results vary with dose, adherence, diet and activity, so trial averages are a guide rather than a promise. Your clinician can set realistic expectations for your situation.
Sources & further reading
- U.S. Food & Drug Administration — prescribing information for Mounjaro (tirzepatide), including Indications, Dosage and Administration, and Boxed Warning.
- SURPASS clinical trial program — tirzepatide in type 2 diabetes, including the SURPASS-2 head-to-head study versus semaglutide.
- SURMOUNT clinical trial program — tirzepatide for chronic weight management (Zepbound).